Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

about

Second-line afatinib administration in an elderly patient with squamous cell carcinoma.Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial.

P2860

Q41823165-A22CD7FF-FB01-4BAD-9DF2-7E873E83FC24 Q42329924-EB69933B-ACA6-4D77-A42C-0F9C50DD4891 Q54114179-BA1BD600-24E4-43B7-B74E-CDF28EFE68C7

P2860

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q38790929

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

@en

type

Item

label

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

@en

prefLabel

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

@en

P1476

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

@en

P2093

Hiroyuki Yasuda

http://www.w3.org/2001/XMLSchema#string

Kenzo Soejima

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Hirano

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

31-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2017.1265446

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27885838

http://www.w3.org/2001/XMLSchema#string

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

about

P2860

P2860

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698